"Record dividend, risky acquisition – Alkem’s Q3 is a mixed bag investors can’t ignore!"

Financial Highlights - Revenue: ₹3,736.82 crore, up 10.7% YoY (₹3,374.28 crore last year). - Net Profit: ₹653.03 crore, up 1.9% YoY (₹640.79 crore last year). - EBITDA: ₹8,280 crore, up 9% YoY, margin at 22.2%. - Other Income: Jumped 53.9% YoY to ₹143.10 crore. - Dividend: Interim dividend of ₹43 per share, the highest in company history. 🔑 Strategic Moves - Acquisition: Signed binding term sheet to acquire 55% stake in Occlutech Holding AG, a Swiss medical devices firm specializing in minimally invasive cardiac implants. - Rationale: Diversification into MedTech, expanding beyond pharma into cardiovascular and orthopedics. 📉 Stock Market Reaction - Despite strong revenue growth and record dividend, shares fell over 8% on NSE after results. - Reasons for decline: - Modest profit growth (only 1.9% YoY). - Concerns over acquisition of loss-making Occlutech (valued at €180 million). - Stock slipped below both 50-day and 100-day moving averages, signaling technical weakness. 🧐 Investor Watchouts - Profitability vs. Growth: Revenue growth is strong, but net profit growth is muted due to higher expenses and tax outgo. - Acquisition Risk: Occlutech is currently loss-making; integration and turnaround will be key. - Dividend Policy: Attractive payout, but sustainability depends on future earnings. - Stock Trend: Technical weakness (below moving averages) suggests near-term volatility. - Sector Outlook: Pharma demand remains steady, but MedTech expansion adds execution risk. ⚖️ Impact on Stock - Short-term: Negative sentiment due to modest profit growth and risky acquisition → pressure on stock price. - Medium-term: If Occlutech integration succeeds, Alkem could gain a strong foothold in global MedTech, boosting valuation. - Long-term: Strong fundamentals in pharma + diversification strategy could support growth, but investors must monitor debt, margins, and MedTech performance.